IRIS
DE LUCA, GIACOMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.524
NA - Nord America 3.710
AS - Asia 3.688
SA - Sud America 854
AF - Africa 84
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
Totale 13.869
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.562
RU - Federazione Russa 2.776
SG - Singapore 1.282
CN - Cina 1.210
BR - Brasile 708
RO - Romania 700
IT - Italia 566
SE - Svezia 474
HK - Hong Kong 458
VN - Vietnam 345
DE - Germania 268
FR - Francia 199
GB - Regno Unito 130
FI - Finlandia 108
IN - India 81
CA - Canada 80
NL - Olanda 71
AR - Argentina 64
AT - Austria 58
JP - Giappone 50
MX - Messico 47
PL - Polonia 42
ZA - Sudafrica 35
BD - Bangladesh 34
TR - Turchia 34
ES - Italia 30
ID - Indonesia 28
PH - Filippine 26
IQ - Iraq 23
EC - Ecuador 22
VE - Venezuela 18
PK - Pakistan 17
UA - Ucraina 17
LT - Lituania 16
CO - Colombia 15
UZ - Uzbekistan 14
AE - Emirati Arabi Uniti 13
IE - Irlanda 13
EG - Egitto 12
PY - Paraguay 12
KR - Corea 10
MA - Marocco 10
BE - Belgio 9
TN - Tunisia 9
CL - Cile 7
GR - Grecia 7
IR - Iran 7
PE - Perù 7
BH - Bahrain 6
NO - Norvegia 6
SA - Arabia Saudita 6
AZ - Azerbaigian 5
LU - Lussemburgo 5
MK - Macedonia 5
MY - Malesia 5
NP - Nepal 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
IL - Israele 4
JM - Giamaica 4
KE - Kenya 4
KZ - Kazakistan 4
LB - Libano 4
XK - ???statistics.table.value.countryCode.XK??? 4
AU - Australia 3
CH - Svizzera 3
DZ - Algeria 3
HN - Honduras 3
JO - Giordania 3
LV - Lettonia 3
PT - Portogallo 3
AO - Angola 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
EU - Europa 2
HR - Croazia 2
HU - Ungheria 2
MN - Mongolia 2
NI - Nicaragua 2
OM - Oman 2
PS - Palestinian Territory 2
SN - Senegal 2
TH - Thailandia 2
TW - Taiwan 2
AL - Albania 1
BB - Barbados 1
BN - Brunei Darussalam 1
BS - Bahamas 1
CR - Costa Rica 1
CU - Cuba 1
CY - Cipro 1
GA - Gabon 1
GT - Guatemala 1
KH - Cambogia 1
LC - Santa Lucia 1
LY - Libia 1
MD - Moldavia 1
PA - Panama 1
Totale 13.864
Salva come PNG Salva come JPEG
Città #
Dallas 1.103
Singapore 667
Moscow 550
Hong Kong 449
Ashburn 447
San Jose 365
Shanghai 254
Beijing 192
New York 168
Hefei 156
Milan 135
Lauterbourg 133
Ho Chi Minh City 127
Los Angeles 112
Lawrence 99
Princeton 99
Munich 96
São Paulo 78
Boardman 63
Nuremberg 62
Helsinki 60
Hanoi 59
Rome 47
Orem 42
Tokyo 40
Santa Clara 39
Warsaw 35
Denver 33
Atlanta 32
Montreal 30
Chicago 29
Johannesburg 29
Rio de Janeiro 29
Chennai 28
Frankfurt am Main 28
Turku 27
Guangzhou 26
Council Bluffs 25
Cesano Boscone 23
Poplar 23
Stockholm 23
Mexico City 22
Da Nang 21
Lappeenranta 20
London 20
Falkenstein 19
Haiphong 18
Amsterdam 17
Ankara 17
Houston 17
Manchester 17
Vienna 17
Brooklyn 16
Seattle 16
Mumbai 14
Tianjin 14
Buffalo 13
Naples 13
Shenzhen 13
The Dalles 13
Toronto 13
Boston 12
City of London 12
Tashkent 12
Belo Horizonte 11
Campinas 11
Dublin 11
Istanbul 11
New Delhi 11
Secaucus 11
Hangzhou 10
Padua 10
Phoenix 10
Porto Alegre 10
Xi'an 10
Can Tho 9
Makati City 9
Brasília 8
Brussels 8
Guayaquil 8
Pietra Ligure 8
Pune 8
Roubaix 8
Seongnam-si 8
Verona 8
Barnet 7
Biên Hòa 7
Brescia 7
Columbus 7
Curitiba 7
Manaus 7
Marília 7
Paris 7
Phủ Lý 7
San Francisco 7
Turin 7
Zhengzhou 7
Ancona 6
Asunción 6
Baghdad 6
Totale 6.728
Salva come PNG Salva come JPEG
Nome #
Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis 455
Intercalated Disc Abnormalities Are Linked to Arrhythmias in Inflammatory Cardiomyopathy 427
Autoantibody positivity predicts severity of rheumatic immune-related adverse events to immune-checkpoint inhibitors 379
Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: data from an Italian multicentre study 345
Serum organ-specific anti-heart and anti-intercalated disk autoantibodies as new autoimmune markers of cardiac involvement in systemic sclerosis: Frequency, clinical and prognostic correlates 230
A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis 229
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 181
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 168
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 161
Myocarditis in anti-synthetase syndrome: clinical features and diagnostic modalities 146
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial 143
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 141
B cells in systemic sclerosis: A possible target for therapy 133
Geographical heterogeneity of clinical and serological phenotypes of systemic sclerosis observed at tertiary referral centres. The experience of the Italian SIR-SPRING registry and review of the world literature 130
Cardiac magnetic resonance findings in acute and post-acute COVID-19 patients with suspected myocarditis 128
Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: An open-label cohort study 126
Does the impact of COVID-19 on patients with systemic sclerosis change over time? 125
Distinctive clinical traits of lupus-related myocarditis: a multicentre retrospective study 121
Adherence to the Mediterranean Diet in Italian Patients With Systemic Sclerosis: An Epidemiologic Survey 120
Arrhythmias in Myocarditis: State of the Art 120
Cardiac magnetic resonance in systemic sclerosis myocarditis: the value of T2 mapping to detect myocardial inflammation 117
Pruritus characteristics in a large Italian cohort of psoriatic patients 116
Clinical profiling and outcomes of viral myocarditis manifesting with ventricular arrhythmias 115
A Novel Histiocytosis With Synovial and Skin Involvement 115
ASSOCIAZIONE TRA MALATTIA IGG4-CORRELATA E IMMUNOTERAPIA ALLERGENE-SPECIFICA. STUDIO EPIDEMIOLOGICO DI UN CENTRO DI RIFERIMENTO ITALIANO. 115
Cardiovascular involvement in Erdheim-Chester diseases is associated with myocardial fibrosis and atrial dysfunction 115
Exercise Stress Test Late after Arrhythmic versus Nonarrhythmic Presentation of Myocarditis 113
Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: The Role of Endomyocardial Biopsy 113
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series 113
Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease 109
C3-glomerulopathy and MGUS: The skin beyond the kidney 109
Therapeutic strategies for primary heart involvement in systemic sclerosis 107
Efficacy and Safety of Methotrexate for the Treatment of Autoimmune Virus-Negative Myocarditis: A Case Series 106
Clinical Applications of FDG-PET Scan in Arrhythmic Myocarditis 104
Calcinosis in systemic sclerosis: An update on pathogenesis, related complications, and management: A heavy burden still waiting to be lifted off patients’ hands 103
Assessing the role of pentraxin-3 in Takayasu's arteritis. Comment on: Plasma pentraxin-3 levels in patients with Takayasu's arteritis during routine follow-up. Alibaz-Oner F. et al 103
Sex-related Differences in Systemic Sclerosis: A Multicenter Cross-sectional Study From the National Registry of the Italian Society for Rheumatology 103
Cardiac Safety of mRNA-based Vaccines in Patients with Systemic Lupus Erythematosus and Lupus-like Disorders with a History of Myocarditis 103
Drug retention rates of biological agents in adult onset Still's disease 102
Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases 102
Drug retention and discontinuation reasons between seven biologics in patients with Takayasu arteritis 101
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production 100
Cardiovascular magnetic resonance parametric mapping in the risk stratification of patients affected by chronic myocarditis 100
Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase 100
Anakinra for the Treatment of Antisynthetase Syndrome: A Monocentric Case Series and a Systematic Literature Review 99
Advances in potential targeted therapies for Erdheim-Chester disease 98
Inflammation as a Predictor of Recurrent Ventricular Tachycardia After Ablation in Patients With Myocarditis 98
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 98
The spectrum of covid-19-associated myocarditis: A patient-tailored multidisciplinary approach 98
Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience 96
DRUG RETENTION RATES OF BIOLOGICAL AGENTS IN ADULT ONSET STILL'S DISEASE IN THE PRE-CANAKINUMAB ERA 96
Canakinumab injection for the treatment of active Still’s disease, including adult-onset Still’s disease 96
Rituximab retention rate in systemic sclerosis: a long term real-life multicentre study 95
Drug development and novel therapeutics to ensure a personalized approach in the treatment of systemic sclerosis 95
Myocarditis as a manifestation of Erdheim–Chester Disease: successful use of anti- IL1 and BRAF inhibitor combination therapy 94
Multimodal Detection and Targeting of Biopsy-Proven Myocardial Inflammation in Genetic Cardiomyopathies: A Pilot Report 92
Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study 92
Immunosuppressive Therapy and Risk Stratification of Patients With Myocarditis Presenting With Ventricular Arrhythmias 92
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 92
Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease 91
Systemic sclerosis Progression INvestiGation (SPRING) Italian registry: demographic and clinico-serological features of scleroderma spectrum 91
Cardiac involvement, a threatening very early manifestation of systemic sclerosis: evidence from VEDOSS patients 90
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry 90
GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study 90
Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases 90
Cardiac Sarcoidosis: Clinical Insights, Diagnosis, and Management Strategies 89
Primary heart involvement in systemic sclerosis, from conventional to innovative targeted therapeutic strategies 89
Anti-Ku syndrome with elevated CK: Association with myocardial involvement in systemic sclerosis 88
Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series 87
Association of anti-RNA polymerase III antibody with silicone breast implants rupture in a multicentre series of Italian patients with systemic sclerosis 86
Pain and Frailty in Hospitalized Older Adults 85
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study 85
Mechanisms of hematopoietic clonal dominance in VEXAS syndrome 84
COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study 84
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies 84
Efficacy and safety of mycophenolate mofetil in patients with virus-negative lymphocytic myocarditis: A prospective cohort study 83
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients 82
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both 80
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 80
Inflammatory rheumatic diseases with onset after SARS-CoV-2 infection or COVID-19 vaccination: a report of 267 cases from the COVID-19 and ASD group 78
The Role of the Multidisciplinary Health Care Team in the Management of Patients with Systemic Sclerosis 78
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis 74
MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION 74
Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study 73
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease 73
Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition 73
Corrigendum to “Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience” [Autoimmunity Reviews, Volume 20, Issue 12, December 2021, 102981](S1568997221002615)(10.1016/j.autrev.2021.102981) 71
Life-threatening arrhythmias in a scleroderma patient: the role of myocardial inflammation in arrhythmic outburst 71
Data standards for transcatheter aortic valve implantation: the European Unified Registries for Heart Care Evaluation and Randomised Trials (EuroHeart) (October, qcac063, 2022) 70
Ventricular Arrhythmias in Myocarditis: Characterization and Relationships With Myocardial Inflammation 70
Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: 'More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia' by Ferraccioli 70
Telemedicine in myocarditis: Evolution of a mutidisciplinary “disease unit” at the time of COVID-19 pandemic 69
Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study 69
Cardiac magnetic resonance in systemic sclerosis patients with cardiac symptoms: do we really need it? 68
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry 67
Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies 66
Hybrid FDG-PET/MR or FDG-PET/CT to Detect Disease Activity in Patients With Persisting Arrhythmias After Myocarditis 65
Immunometabolic activation of macrophages leads to cytokine production in the pathogenesis of KRAS-mutated histiocytosis 65
Treatment of Dilated Cardiomyopathy With Interleukin-1 Inhibition 64
Unexpected acute lymphocytic virus-negative myocarditis in a patient with limited cutaneous systemic sclerosis: a case report 64
Totale 11.223
Salva come PNG Salva come JPEG
Categoria #
all - tutte 66.349
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 66.349
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20216 0 0 0 0 0 0 0 0 0 0 4 2
2021/2022249 1 0 102 46 9 16 4 7 11 31 5 17
2022/2023784 250 176 55 4 16 97 40 72 35 11 15 13
2023/2024744 25 56 75 67 65 111 42 82 5 33 36 147
2024/20253.364 224 41 102 104 130 218 1.093 331 388 233 200 300
2025/20269.043 612 868 944 1.147 707 286 724 665 2.473 491 126 0
Totale 14.271